In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Adam Zamecnik


London, UK

Adam has previously worked at GlobalData Media as a Healthcare Reporter, writing longer and shorter articles for the public website Pharmaceutical Technology and the Pharma Intelligence Centre. During his time there, Adam focused on topics such as cell and gene therapy, vaccine research, and new approaches to the treatment of haematological conditions. He has also covered the development of new biosimilars, the production of complex generics, and legal battles between Big Pharma. Prior to this, Adam wrote as a freelance reporter for the likes of Vice World News. Adam holds an MA in International Journalism from City, University of London.

Latest From Adam Zamecnik

Amneal Launches Polysorbate-Free Fosaprepitant In The US

Marking the firm’s second launch of a 505(b)(2) injectable this year, Amneal has released Focinvez in the US as an antiemetic agent used in chemotherapy regimens.

United States BioPharmaceutical

Hikma Launches First US Sodium Acetate With CGT Exclusivity

Following on from a flurry of deal and launches, Hikma has released another product onto the US market with the first of its sodium acetate injections, bolstered by 180 days of Competitive Generic Therapy exclusivity. 

BioPharmaceutical United States

Hyloris Replaces Leadership After Continued Transaction Woes

Marking a further development in the story of Hyloris’ in-licensing deal with QliniQ, the company’s board has announced significant leadership and organizational changes to address potential concerns.

BioPharmaceutical Belgium

ANI Acquires Alimera Sciences To Bolster Ophthalmology Portfolio

ANI has acquired Alimera Sciences in a move to expand its rare disease business, highlighting its increasing drift from generics.

United States BioPharmaceutical

Apotex Secures Canadian License For Loqtorzi From Coherus

After announcing a pivot to innovative oncology treatments from biosimilars, Coherus has granted an exclusive license for its novel biologic cancer therapy Loqtorzi to Apotex in Canada.

Canada Biologics

Dr Reddy’s Acquiring Haleon NRTs Available Outside US In Deal Worth Up To $632M

The Indian player made another high-level deal that grants it rights to nicotine replacement therapies in over 30 countries, following on from its recent announcements with Nestlé.

OTC Drugs Deals
See All